Pipeline

Our pipeline from Phase 1 to registration includes 90 investigational therapies, which are focused in areas where
we have the potential to bring differentiated, high value therapies and vaccines to patients faster.

Programs in Clinical Trials or Registration

Our clinical research activities are focused on translating novel science into therapies and vaccines. Today,
our clinical pipeline includes targeted immunotherapies, which have the potential to be part of the next generation of cancer
therapy; first-in-class vaccines with the potential to help prevent two deadly hospital-acquired infections; antibodies that may be
potentially useful in treating lupus and inflammatory bowel disease; and, a potential new therapy for Parkinson's disease. We are also
applying our expertise in developing safe and effective biologic medicines to develop high quality biosimilars that may provide
patients with access to alternative biologic therapies.